Document ID: chunk:federal_register_of_legislation:F2023L01745:schedule:1:p40
Version: federal_register_of_legislation:F2023L01745
Segment Type: schedule
Provision Reference: sch 1 (pt 40/42)
Character Range: 140682–144245

after existing text:
   C14758     Complex refractory Fistulising Crohn disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Written Authority Required procedures
              Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
              Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND
              Patient must not have failed PBS-subsidised therapy with this drug for this condition more than once in the current treatment cycle.
              Must be treated by a gastroenterologist (code 87); OR
              Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR
              Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)].
              To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted between 8 and 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.
              Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.
              Applications for authorisation must be made in writing and must include:
              (1) two completed authority prescription forms; and
              (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the following:
              (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
              (ii) details of prior biological medicine treatment including details of date and duration of treatment.
              Two completed authority prescriptions should be submitted with every initial application for this drug. One prescription should be written under S100 (Highly Specialised Drugs) for a weight-based loading dose, containing a quantity of up to 4 vials of 130 mg and no repeats. The second prescription should be written under S85 (General) for 1 vial or pre-filled syringe of 90 mg and no repeats.
              The most recent fistula assessment must be no more than 4 weeks old at the time of application.
              A maximum quantity of a weight-based loading dose is up to 4 vials with no repeats and the subsequent first dose of 90 mg with no repeats provide for an initial 16-week course of this drug will be authorised
              Where fewer than 6 vials in